Viatris sells LatAm rights to Viagra, Lipitor brands to Aspen Pharmacare

Posté le 22 nov. 2023

Viatris has sold the commercialization rights and related intellectual property for a portfolio of well-known branded products in Latin America, such as Lipitor, Viagra, Lyrica, Zoloft, Norvasc and Celebrex, to South Africa-based pharmaceutical group Aspen Pharmacare.

Viatris is a major global pharmaceutical company, publicly listed on the New York Nasdaq and with principal offices in Canonsburg, Pennsylvania, in the US.

The assets relating to the products being acquired comprise intellectual property required for their commercialization, and any related goodwill owned by Viatris and its subsidiaries; product registrations and marketing authorizations; and the related inventory.

The deal was valued at $280 million, according to the value of the product brands determined by Aspen Pharmacare. The deal was settled through a combination of a cash payment of $150 million and an extension of supply terms to Viatris.

The transaction is conditional upon the approvals of the competition authorities in Ecuador and Colombia.

Aspen and Viatris will also conclude supply agreements whereby AGI will be supplied with the products for at least seven years.

The products generated sales of about $92 million in 2022.

Chilean law firm Carey acted as local counsel to Viatris on the deal, with a team led by partner Marcos Ríos, with counsel José Ignacio Mercado and associates José Santos Ossa, Juan Pablo De la Maza and Constanza Trisotti.

Law firm Cravath, Swaine & Moore also acted as counsel to Viatris.